主要观点总结
本文介绍了药物研发过程中的挑战和药物候选分子的不完美性，强调了在药物开发过程中需要平衡各种药物特性并做出明智的决策。文章还提到了一场关于药物开发的直播活动，将由经验丰富的药物发现科学家和市场苗博士分享关于药物开发的知识和经验。活动组织者是BioSpark集团，该机构致力于推动生命科学领域的高级人才交流和跨界交流。
关键观点总结
关键观点1: 药物研发的挑战和药物候选分子的不完美性
药物研发是一个漫长而艰巨的过程，只有极少数的药物候选分子能够顺利通过所有临床试验并到达市场。每个药物候选分子都有一些缺陷，没有完美的分子能满足所有要求。开发者需要平衡各种药物特性，并做出明智的决策。
关键观点2: 直播活动内容
本次直播将聚焦于药物开发的各个方面，包括从药物代谢、药理学、临床药理学等角度讨论为什么存在没有理想的药物分子，以及如何管理每个药物候选分子的缺陷。还将分享一个成功开发新药的经验，尤其是针对新药的临床前评估和药理学研究方面。
关键观点3: 活动组织者介绍
本次活动的组织者BioSpark集团是一个非盈利机构，致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞。
文章预览
立即预约直播 汇聚群英智慧，闪亮你我星光 Together, Spark Biomedicine! Drug discovery and development is a long and arduous journey and only a tiny fraction of drug candidates can survive all clinical trials and reach the market. For a drug candidate to be selected and successfully developed, it has to meet the requirements of numerous drug-like properties in biology, pharmacology, pharmacokinetics, toxicology, and manufacturability. Every drug candidate has some flaws and there's no perfect molecule that can meet all these requirements. Drug developers have to balance all these properties and make calculated decisions when advancing a drug candidate. From drug metabolism, pharmacokinetics, and clinical pharmacology perspectives, this presentation will highlight why there are no ideal PK profiles and no perfect molecules and how we can manage the flaws in every drug candidate. The case and story of avacopan, a recently approved drug which had many near-death experi
………………………………
